StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

CANF has been the subject of several other research reports. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

CANF opened at $1.91 on Wednesday. Can-Fite BioPharma has a 1 year low of $1.29 and a 1 year high of $4.69. The company has a market capitalization of $5.52 million, a price-to-earnings ratio of -1.07 and a beta of 1.33. The firm’s fifty day moving average price is $1.54 and its two-hundred day moving average price is $1.98.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.